Sun Pharma Q1FY24 Results: Consolidated PAT of Rs. 2022.54 Cr

Sun Pharma to buy 38% stake in Ezerx Health Tech for Rs 28.69 Cr

Sun Pharma Q1 results show revenue up from 11303.95 crores to 12145.28 crores, a 6.93% increase in growth. EPS rise from ₹8.3 to ₹8.4, up by 1.20%.

First, Let’s Begin with Quarter-on-Quarter Basis:

Sun Pharma shared its Q1 results on Thursday. They earned 12145.28 crores in revenue this quarter, but that’s more than the 11303.95 crores they made last quarter. The company’s growth increased by 6.93 percent when comparing the two quarters.

In terms of profits, the company’s PAT (Profit After Tax) for this quarter was 2022.54 crores, up from 1984.47 crores in the previous quarter. Their quarter-to-quarter growth increased by 1.92 percent.

The company’s EPS (Earnings Per Share) this quarter is ₹8.4, which is an increase of 1.20% from the ₹8.3 EPS in the previous quarter.

Now, Let’s Analyze the Results on a Year-over-Year Basis:

The company made a total revenue of 12145.28 crores this year (2023), which is 12.83 percent higher than last year’s total revenue of 10763.90 crores.

This year’s PAT (Profit After Tax) is 2022.54 crores, which is also 1.86% lower than last year’s PAT of 2060.88 crores.

The EPS (Earnings Per Share) for this year is ₹8.4, which is 2.33% less than the EPS of ₹8.6 earned last year.

Sun Pharma Share Dividend Announcement / Record Date:

The record date for the dividend has not arrived yet.

About Sun Pharma:

Sun Pharmaceutical Industries Limited, headquartered in Mumbai, is an Indian multinational pharmaceutical company. It operates in over 100 countries worldwide, manufacturing and marketing pharmaceutical formulations and active pharmaceutical ingredients.

Download the Full PDF of Sun Pharma Q1 Results: Click Here

For more of the Latest News, Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *